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Abstract
Background: To fully understand the burden of hepatitis C (HCV) infection in Ghana towards informing appropriate
preventive measures, accurate prevalence estimates are needed. In this study, we estimate the prevalence of chronic
HCV infection by systematically reviewing primary studies published between 1995 and 2015.
Methods: A systematic review and meta-analysis was conducted as per the PRISMA guidelines. Comprehensive
searches for hepatitis C prevalence studies for the years 1995–2015 were conducted in PubMed, ScienceDirect, Google
Scholar, Africa Journals Online (AJOL) and the WHO African Index Medicus databases. We also searched the websites of
the ministry of health and Ghana Health service for non-indexed studies or reports on the subject. Further systematic
reference screening of published reviews and retrieved studies were also conducted to identify additional publications
not captured through the online searches.
Results: Twenty-Four (24) studies from nine regions of Ghana with a combined sample size of 100,782 were analyzed.
No study involving participants from Upper West region was retrieved. The national prevalence of chronic HCV was
estimated as 3.0 % (95 % CI = 2.6 % to 3.5 %; I2 = 97.61 %, p < 0. 001). Prevalence rates of chronic HCV infection among
blood donors was 2.6 % (95 % CI = 2.1 % to 3.1 %; I2 = 98.33 %, p < 0.001) with higher prevalence rate estimated for
replacement blood donors (RBDs) than voluntary blood donors (RBDs). Among pregnant women and parturients, anti-
HCV seroprevalence was estimated as 4.6 % (95 % CI = 1.8 % to 7.5 %; I2 = 75.74 %, p = 0.016). The national prevalence
of HIV/HCV co-infection was also estimated as 2.8 % (95 % CI = 0.4-6 %; I2 = 65.86 %, p = 0.0053). Regional prevalence of
chronic HCV infection were determined for Ashanti (1.5 %, 95 % CI = 1.2 % to 1.9 %; I2 = 96.24 %, p < 0.001) and Greater
Accra (6.4 %, 95 % CI = 4.2 % to 8.6 %; I2 = I2 = 88.5 %, P < 0. 001) regions but no estimates were available for the other
eight regions. The ascending order of HCV prevalence rates according to years in which studies were conducted was
2006–2010 < 2011–2015 < 1995–2002 < 2001–2005. Higher prevalence of chronic HCV infection was estimated for rural
(5.7; 95 % CI 5.0–6.3 %; I2 = 0, p = 0.804) than urban (2.6 %, 95 % CI = 2.1 % to 3.0 %; I2 = 97.3 %, p = 0.0001) settings.
Conclusion: Our study demonstrates a high prevalence of chronic hepatitis C infection in Ghana. This highlights the
urgent need for stronger commitments from government and all stakeholders within the country to outline efficient
preventive and curative measures towards reducing the overall burden of the disease.
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Background
Hepatitis C virus (HCV) infection is now considered to be
of significant global health importance affecting all coun-
tries and requires the needed attention [1]. About 2.8 % of
the world’s population representing almost 180 million in-
dividuals are estimated to be infected with HCV; as much
as 80 % of this number suffer chronic infection—almost
five times the number for HIV [2]. Although, recent esti-
mates point to a declining burden mainly due to reduced
prevalence among children, it is widely accepted that
more needs to be done to control the disease [3].
Chronic HCV infection has been strongly implicated
in the development of hepatocellular carcinoma (HCC).
About 10–20 % of chronic HCV sufferers develop liver
cirrhosis within 20–30 years of onset of infection, 1–5 %
of these are likely to progress into liver cancer [4, 5].
Each year, more than 350,000 deaths from HCV-related
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liver diseases are recorded across the globe with majority
of these deaths arising from liver cirrhosis and HCC [6].
Over 25 % of the global cases of liver cirrhosis and HCC
are attributable to chronic HCV infection, with rates
higher in endemic regions [7].
There are variations in the burden of HCV across the
globe as depicted by prevalence rates of 1.5 %, 2.3 % and
3.2 % for the World Health Organization (WHO)’s
Americas, Europe and Africa regions, respectively [1].
Madhava et al. [8] estimated the HCV prevalence in 2002
in Sub-Saharan Africa to be 3.0 % with a prevalence rate of
2.4 % for the West African region where Ghana is located.
Recent estimate by Rao et al. [9] presents a slightly lower
prevalence of 2.65 % for the Sub-Saharan Africa region.
However, there are concerns that prevalence rates
reported for Sub-Saharan Africa may be substantially
underestimated owing to factors such as the limited
availability of HCV representative surveys in the region
[10]. Aside the regional variations in HCV prevalence,
even within countries, the patterns of HCV epidemiology
vary greatly. In the United States for instance, highest
HCV prevalence is recorded among persons 30-49 years,
although in countries like Italy and China, persons
>50 years account for most infections [11].
It is important to highlight that there are some real
challenges in documenting an accurate burden of HCV
to ascertain true incidence and prevalence in any country.
Such challenges include for instance, the unavailability of
assays with ability to distinguish acute and chronic infec-
tions as majority of acute HCV infections often present no
symptoms [12].
Globally, where the impact of HCV has been thoroughly
studied, the implications on national health systems has
been found to be enormous [13]. Razavi et al. [14] esti-
mated the lifetime cost of a person infected with HCV in
2011 in US to be at $64,490, although, this could rise to
$205,760 ($154,890–$486,890) when medical inflation is
applied. Myer et al. [15] also estimated an amount of
$64,694 as the lifetime cost for Canadian with HCV infec-
tion in 2013 which could rise to as high as $327,608 if liver
transplantation becomes necessary.
Viral hepatitis including HCV, are considered to be
significant contributors to morbidity and mortality in
Ghana and deserve greater attention [16]. However, ex-
tensive aggregate data on prevalence of HCV in Ghana
are currently lacking [17]. Lavanchy [1] reported a na-
tional HCV prevalence rate of 1.7 % for Ghana in 2010
based on WHO’s data. A systematic review focusing on
HCV seroprevalence in Africa by Riou et al. [18] also re-
ported an HCV prevalence rate for Ghana within the range
0.2–9.4 %. Aside the very wide range presented by this
study, the estimate was also based on only ten studies and
was restricted to adult populations. To the best of our
knowledge, no other thoroughly conducted systematic
review and meta-analysis on the prevalence of chronic
HCV infection in Ghana has been published. This obser-
vation further highlight the lack of thorough compilation
of the evidence regarding the prevalence of HCV in
Ghana.
To inform evidence-based policymaking, public health
research and programming prioritization in Ghana, ac-
curate prevalence estimates based on thorough and up-
to-date evidence complication is essentially needed. In
this paper, we aimed at estimating the prevalence of
chronic HCV infection in Ghana based on studies pub-
lished over the last two decades (1995–2015). This was a
contribution to our large study documenting the burden
of common viral hepatitis in Ghana.
Methods
This review was conducted in accordance with recom-
mendations outlined in the PRISMA (Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses)
statement [19].
Search strategy
We conducted searches in PubMed, Science Direct,
Google scholar, Africa Journals Online (AJOL) and the
WHO African Index Medicus databases to identify en-
tries on HCV prevalence in Ghana up to 31st December
2015. The key words used were Hepatitis C, prevalence
and Ghana and similar terms such as HCV and anti-
HCV were crossed. The main limits used were ‘Humans’
and ‘English’. The specific search sequence for PubMed
are as follows; ((“hepatitis c”[MeSH Terms] OR “hepaci-
virus” [MeSH Terms] OR Hepatitis C [Text Word] OR
“hepatitis c antibodies”[MeSH Terms] OR anti-HCV
[Text Word] OR HCV [All Fields])) AND (“prevalence”
[MeSH Terms] OR prevalence [Text Word])) AND
(“ghana” [MeSH Terms] OR ghana[Text Word])).
We also searched the websites of the ministry of
health (http://www.moh-ghana.org/) and Ghana Health
service (http://www.ghanahealthservice.org/) for non-
indexed studies or reports on the subject. Cross-checking
of bibliographies from other published reviews and from
all retrieved articles was conducted to identify additional
publications.
Studies inclusion criteria
We included only primary studies published in English
between January 1995 and December 2015 and which
reported chronic HCV prevalence information among
Ghanaians. This period was considered as we were pri-
marily interested in looking at HCV prevalence over the
last two decades. For a study to be included, the diagno-
sis of HCV should have been based on serological assays
that detect antibodies to HCV; or molecular assays that
aim to detect, quantify, and/or characterize HCV-RNA
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genomes [20]. No age restrictions were imposed and we
considered studies conducted in both children and
adults.
Data extraction and quality assessment
Two reviewers (RO, AA) screened titles and abstracts
against predefined study inclusion criteria. Full-text articles
were also independently screened by the same reviewers
(AA, RO) for eligibility. Quality appraisal of studies were
carried out using a 12-point scoring system modified from
the Downs and Black checklist as adopted in similar re-
views [21, 22]. The criteria included for instance, whether
study’s objective was clearly defined, study design clearly
described, whether participants were described (e.g. blood
donors, IDUs) and are representative of general population
and whether ample sample size was adequate. Additionally,
other measures such as whether studies accounted for
missing data, cofounders discussed, and whether socioeco-
nomic variables such as age, gender, setting (e.g. urban or
rural) were fully described. Attention was also paid to
whether studies reported methods by which HCV status
were determined and whether the outcomes of interest
were clearly spelt out and any biases reported. Studies were
graded according to their scores into high, medium or low.
We collected further descriptive information such as author
details, study’s publication year, region of Ghana and the re-
ported HCV prevalence. Prevalence data were independ-
ently extracted by AA and AM and crosschecked by RO.
Any discrepancies were resolved through consensus-based
discussions.
Data analysis
We conducted a meta-analysis using Open Meta (ana-
lyst) software, an open-source, cross-platform software
for advanced meta-analysis [23] and StatsDirect statis-
tical software (Version 3.0.0, StatsDirect Ltd, Cheshire
UK) [24]. The pooled and individual study proportions
were assessed at 95 % confidence interval. We tested for
heterogeneity based on Cohran’s Q statistic test and de-
gree of inconsistency (I2) [25]. An I2 > 50 % was consid-
ered as representing meaningful heterogeneity. In this
case, the random effect model (DerSimonian-Laird) was
adopted over fixed effect model in the analysis of pooled
effects [25]. We carried out direct observation of funnel
plots to detect presence of publication bias and this was
confirmed with Egger and Harbord statistics tests [26,
27]. A leave-one-out sensitivity analysis was carried out
to assess the impact of each study on the overall pooled
estimate [28]. Sub-analysis was carried out for different
study periods as well as for specific populations (e.g.
HIV patients, blood donors etc.) and regions of Ghana.
In all computations, statistical significance was set at
p < 0.05.
Results
Studies identification and characteristics
Figure 1 summarises the studies retrieval steps. A total
of 874 citations were retrieved from the searches. Follow-
ing, titles and abstract screening, removal of duplicate,
and full-text analysis and referencing screening, 24 studies
met the inclusion criteria for inclusion in the overall ana-
lysis [17, 29–51]. The 24 studies (Table 1) which were con-
ducted in nine regions of Ghana altogether involved a
sample size of 100,782. The regional distribution of studies
were, Ashanti (12), Greater Accra (6), Northern (1),
Brong-Ahafo (1), Central (1), Upper East (1) and two (2)
multi-regional studies. Majority of the studies (87.5 %, n =
21) were conducted among urban residents. According to
publication years, 25 % (n = 6), 33 % (n = 8) and 42 %
(n = 10) of studies were published within the periods
1995–2002, 2003–2009 and 2010–2015 respectively.
Sample sizes across the 24 studies ranged from 110 to
51,100. A significant proportion (54 %, n = 13) of the stud-
ies were conducted among blood donors (either replace-
ment or voluntary donors) participants. Only one study
was specifically conducted in children [44]. Three studies
were conducted among specific disease group of patients
(diabetes and HIV). The quality appraisal scores graded 4
%, 38 % and 58 %, of studies to be of low, medium and
high quality, respectively.
Overall national prevalence
The reported anti-HCV prevalence rate across the 24
studies ranged from 0 % to 20.1 %. In 63 % (15/24) of
studies, the reported prevalence was more than 2 %— the
level at which anti-HCV prevalence rate is considered to
be high [52]. 42 % of studies reported prevalence rates at
least 200 % higher than the 2 % level. The pooled national
prevalence estimate (Fig. 2) was determined as 3.0 %
(95 % CI = 2.6 % to 3.5 %). The result of heterogeneity
(I2) was also 97.61 % (p < 0.001) for the degree of
inconsistency.
Blood donors
A total of thirteen (13) studies involved blood donor
participants (voluntary and family replacement donors),
although data on anti-HCV prevalence for this specific
population obtained from twelve (12) studies. The 12
studies altogether involved a sample size of 95,706. The
reported HCV prevalence was in the range of 0.22 to
8.4 %. The pooled estimate of HCV prevalence among
blood donors (Fig. 3) across the twelve (12) studies was
2.6 % (95 % CI = 2.1 % to 3.1 %). The result of hetero-
geneity (I2) was also 98.33 % (p < 0.001) for the degree of
inconsistency. Separate prevalence for VBDs and RBDs
were retrieved from five studies [34, 38, 43, 47, 49]. The
pooled prevalence of HCV prevalence rate for VBDs was
determined as 0.3 % (95 % CI 0.1–0.5 %). The result of
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heterogeneity (I2) was also 69.04 % (p < 0.0001) for the
degree of inconsistency. On the other hand, the pooled
HCV prevalence for RBDs was determined as 1.8 %
(95 % CI 0.9–2.6 %). The result of heterogeneity (I2) was
determined as 95.42 % (p < 0.001). The prevalence differ-
ence of 1.5 % (95 % CI 1.3–1.8 %) between RBDs and
VBDs was found to be statistically significant (p < 0.0001).
Pregnant women and parturients
Four studies involved pregnant women and parturient
participants [36, 41, 44, 51]. One of these studies [51],
did not present any specific prevalence data on pregnant
women and thus was excluded from this analysis. Hence
anti-HCV prevalence among pregnant women and par-
turients were retrieved from three studies which to-
gether involved a total of 1,100 participants. The HCV
prevalence across these studies was within the range 2.5
to 7.7 %. The pooled HCV prevalence estimate for the
pregnant women and parturients was determined as
4.6 % (95 % CI = 1.8 % to 7.5 %) (Fig. 4). The result of
heterogeneity (I2) was determined as 75.74 % (p = 0.016)
for the degree of inconsistency.
High risk groups
Persons at greater risk of chronic HCV include injection
drug users (IDUs), HIV patients, people in custodial set-
tings and commercial sex workers [53–55]. Two studies
[31, 32] were conducted in prisons although data among
prisoners was retrieved from only one study [31]. An ex-
tremely high (19.2 %) prevalence of HCV was recorded
among the incarcerated persons. Reported illegal drug
use was high among this group (83.2 % reporting using
marijuana, 7.3 % reported cocaine use, 5.2 % indicate
history of heroin abuse and 4.2 % used phencyclidine)
Fig. 1 A PRISMA flow chart of studies’ retrieval steps
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Table 1 Descriptive characteristics of studies reporting chronic HCV prevalence in Ghana
Study No Author details Year of publication Design Region of study Study population Age group
(yrs.)
Setting Sample size (n) Method Anti-HCV (%) Quality
grade
1 Acquaye and Tetteh-
donkor. [29]
2000 Cross-sectional Greater Accra Blood donors€ n.s Urban 1300 ELISA 5.2 Medium
2 Adoba et al. [30] 2015 Cross-sectional Ashanti Barbers 28.18a urban 200 Rapid test 0.5 High




17–84 Urban 363 ELISA 20.1 High
4 Adjei et al. [32] 2008 Cross-sectional National (Excludes
Upper East & West)
Prison Officers 38.1b Urban 445 ELISA 18.7 High
5 Allain et al. [33] 2009 Cross-sectional Ashanti Blood donors€ >16 Urban 51100 Rapid test 0.4 High
6 Allain et al. [34] 2010 Cross-sectional Ashanti Blood donors€ 31.0a Urban 11000 Rapid test 0.22 High
7 Amidu et al. [35] 2010 Cross-sectional Upper East Blood donors€ 17-58 Urban 4146 Rapid test 3.6 Medium
8 Ampofo et al. [17] 2002 Cross-sectional Greater Accra Blood donors€ 16-60 Urban 808 Agglutination
assay
8.4 High
9 Apea-Kubi et al. [36] 2006 Cross-sectional Greater Accra Pregnant & non-
pregnant women
29.6a Urban 517 Rapid test 5.2 High
10 Blankson et al. [37] 2005 Case-control Greater Accra Cirrhotic & non-
cirrhotic patients
15–90 Urban 350 ELISA 4.3 High
11 Candotti et al. [38] 2001 Cross-sectional Ashanti Blood donors€ 32a Urban 2738 EIA 1.3 High
12 Candotti et al. [39] 2003 Cross-sectional Ashanti Blood donors€ 29a Urban 4984 EIA 1.3 Medium
13 Ephraim et al. [40] 2014 Cross-sectional Central Diabetics n.s Urban 110 Rapid test 0.0 Medium
14 Ephraim et al. [41] 2015 Cross-sectional Ashanti Pregnant women 10–40 Urban 168 Rapid test 7.7 Medium
15 King et al. [42] 2014 Cross-sectional Ashanti HIV+ individuals n.s Urban 408 Plasma assay 1.0 High
16 Kubio et al. [43] 2012 Register Review Northern Blood donors€ n.s Rural 819 n.s 6.1 Low
17 Lassey et al. [44] 2004 Cross-sectional Greater Accra Parturients n.s Urban 638 ELISA 2.5 Medium
18 Martinson et al. [45] 1996 Cross-sectional Ashanti Children 6–18 rural 803 n.s 5.4 Medium
19 Nkrumah et al. [46] 2011 Cross-sectional Ashanti Blood donors€ 26–35 Rural 2773 Rapid test 5.63 Medium
20 Owusu-Ofori et al. [47] 2005 Cross-sectional Ashanti Blood donors€ n.s Urban 9372 Rapid test 0.5 High
21 Sagoe et al. [48] 2012 Cross-sectional Greater Accra HIV+ individuals ≥18 Urban 138 Plasma assay 3.6 High
22 Sarkodie et al. [49] 2001 Cross-sectional Ashanti Blood donors€ 16–52 Urban 3264 Mixed methods 1.6 High
23 Walana et al. [50] 2014 Cross-sectional Brong-Ahafo Blood donors€ 20–49 Urban 3402 ICT 4.4 Medium
24 Wansbrough-Jones et al. [51] 1998 Cross-sectional Ashanti Pregnant women
& blood donors€
15–60 Urban 936 ELISA 2.8 High
n.s not specified, ICT immunochromatography, ELISA enzyme-linked immunosorbent assay, EIA enzyme immunoassays, anti-HCV hepatitis C antibody
aaverage
bmedian















[31]. Prevalence of HCV among HIV positive individuals
was retrieved from three studies [42, 43, 48]. The pooled
prevalence of chronic HCV among HIV patients from the
three studies was determined as 2.8 % (95 % CI = 0.4–6 %).
The result of heterogeneity (I2) was determined as 65.86 %
(p = 0.0053) for the degree of inconsistency. No study
reported individual prevalence rate among IUDs as well
as for commercial sex workers.
HCV prevalence for rural and urban settings
Three (3) studies were conducted among rural dwellers
[43, 45, 46]. These studies involved a total of 4,395 par-
ticipants and reported individual HCV prevalence ran-
ging from 5.4 to 6.1 %. The pooled HCV prevalence
estimate for urban setting was determined as 5.7 %
(95 % CI 5.0–6.3 %; I2 = 0; p = 0.804). Twenty-one (21)
studies involved urban dwellers and together included a
Fig. 2 Forest plot of studies reporting chronic HCV infection prevalence in Ghana
Fig. 3 Forest plot of studies reporting chronic HCV prevalence among blood donors in Ghana
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total of 96,387 participants. The reported individual
HCV prevalence ranged from 0 to 20.1 %. The pooled
prevalence estimate (Fig. 5) for the studies conducted
in urban settings was 2.6 % (95 % CI = 2.1 % to 3.0 %).
The result of heterogeneity (I2) was determined as 97.3 %
(p = 0.001) for the degree of inconsistency. The difference
in pooled HCV prevalence estimates for rural and urban
settings was statistically significant (p < 0.002).
Regional prevalence
Pooled HCV prevalence estimate for the Ashanti region
was estimated from 13 studies which altogether involved
87,805 participants. The reported HCV prevalence rates
across the thirteen (13) studies ranged from 0.22 to
11.9 %. The pooled HCV prevalence estimate for Ashanti
region was determined as 1.5 % (95 % CI = 1.2 to 1.9 %;
I2 = 96.24; p < 0.001). Pooled HCV prevalence for the
Greater-Accra Region, was estimated from eight studies
which altogether involved 4,063 participants. The re-
ported individual HCV prevalence from the eight
studies ranged from 2.5 to 17.8 %. The pooled HCV
prevalence for the Greater-Accra region was deter-
mined as 6.4 % (95 % CI = 4.2 % to 8.6; I2 = 88.5 %; p <
0.001). We were unable to deduce aggregate data for
Eastern, Upper East, Brong-Ahafo, Central, Northern,
Western and Volta regions due to limited number of
Fig. 4 Forest plot of studies reporting chronic HCV prevalence amongst pregnant women and parturients in Ghana
Fig. 5 Forest plot of HCV infection for studies conducted in urban and rural parts of Ghana
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studies and no single reported data was available for
Upper West region (Fig. 6).
HCV prevalence according to periods in which studies
were conducted
Studies were grouped according to the mid-year of the
period in which they were undertaken. The four period
groupings were 1995–2000, 2001–2005, 2006–2010 and
2011–2015. Among the seven studies conducted within
the period 1995–2000 which involved a total 14,833
participants, the reported individual HCV prevalence
ranged from 1.3 to 8.4 %. The pooled HCV prevalence
estimates for the studies conducted in the period 1995–
2000 was 3.4 % (95 % CI 2.3 to 4.4 %; I2 = 94.76; p < 0.001).
The seven studies conducted within the period 2001–2005
also involved a sample population of 15,831 and reported
HCV prevalence within the range of 0.5–20.5 %. The
pooled HCV prevalence estimate for the studies con-
ducted in the period 2001–2005 was determined as 6.9 %
(95 % CI 4.4 to 9.4 %; I2 = 98.16; p < 0.001). Five studies
Fig. 6 A map of chronic HCV prevalence across regions of Ghana
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were conducted in the period 2006–2010 and together in-
volved 65,830 participants and reported HCV prevalence
ranging from 0.2 to 6.1 % with a pooled HCV prevalence
estimate of 2.0 % (95 % CI 1.4–2.6 %; I2 = 98.08; p < 0.001).
Among the five studies conducted within the period
2011–2015 which altogether involved a total of 14,833
participants, the reported HCV prevalence ranged from
1.3 to 8.4 %. The pooled estimate for the studies con-
ducted in the period 2011–2015 was 2.4 % (95 % CI =0.3
to 4.5 %; I2 = 94.42; p < 0.001). Hence the order of ascend-
ing HCV infection prevalence rates according to years in
which studies were conducted was 2006–2010 < 2011–
2015 < 1995–2002 < 2001–2005 (Fig. 7).
Heterogeneity assessment
A direct observation of funnel plot revealed an asymmet-
rical display of the HCV prevalence reported by the vari-
ous studies (Fig. 8). The presence of publication bias was
confirmed by statistically significant Egger (p < 0.0001)
and Harbord (P = 0.0002) tests. A leave-one-out analysis
which was performed to assess the impact of the various
studies on the pooled estimates [32], showed that the
pooled HCV prevalence estimate was dominated by Allain
et al. [37] and Allain et al. [38]. The most dominant studies
all involved blood donors (Fig. 9).
Discussion
In this review, we present a high prevalence (3.0 %) of
chronic HCV infection in Ghana. This prevalence rate is
significantly higher than the national prevalence of 1.7 %
reported previously by Lavanchy [1]. The observation of
higher prevalence rate in this study may be in alignment
with the observation by Layden et al. [10] that HCV
prevalence rates for sub-Saharan Africa have generally
been underestimated in the past. Even that, the preva-
lence rate reported may still be modest considering that
a significant proportion of studies included in this re-
view involved low risk populations such as blood donors
who are often biased towards a healthier population
[56]. Additionally, as highlighted in the sensitivity analysis,
the anti-HCV prevalence was most impacted by two
studies all conducted in blood donors [37, 38]. In devel-
oped countries like Australia and the US, prevalence of
chronic HCV infection has been estimated to be less than
2 % [7]. This may highlight that the level of chronic HCV
infection in Ghana may be considerably high.
The high prevalence of chronic HCV infection together
with previously reported high prevalence of other viral
hepatitis in Ghana [57], points to a growing concern re-
garding the safety of blood products in the country. Al-
though, Ghana has a national blood policy which requires
that all donated blood are screened for blood-borne infec-
tions including HIV 1 and 2, Hepatitis B (HBV), HCV and
Syphilis [58], a greater emphasis and stricter monitoring
to ensure high levels of adherence to this policy will be
needed to minimise the risk of supplying contaminated
blood to patients.
The prevalence of chronic HCV infection among preg-
nant women was estimated as 4.6 % which is high when
reference is made to other regions like the United States
and Europe where prevalence of chronic HCV among
this group has been estimated to be around 1–2.5 %
[59]. Our result therefore highlight the importance of
vertical transmission in the overall spread of HCV infec-
tion in Ghana. Studies have demonstrated that chronic
HCV infection during pregnancy poses significant risks
to mother and child and may further exacerbate the
risks of preterm delivery, low birth weight, congenital
malformations, glucose intolerance during pregnancy
and overall perinatal mortality [60, 61]. The high HCV
prevalence among pregnant women draws attention to
the need for the adoption of a national program that in-
cludes HCV screening for all or most-at-risk pregnant
women in Ghana. Although, a vaccine to prevent HCV
infection is currently non-existent, treatment with prep-
arations such as interferon for women with high HCV
viral load will lead to reduction in HCV infection levels
for the women and also minimise the risks of vertical
transmission of the disease in future pregnancies [59].
Several factors may contribute to the observed high
levels of chronic HCV infection in Ghana. Studies have
reported low levels of awareness and knowledge among
Fig. 7 HCV infection prevalence according to periods in which studies were conducted
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Fig. 8 A funnel plot of studies reporting chronic HCV infection prevalence in Ghana
Fig. 9 A leave-one-out sensitivity plot of studies reporting chronic HCV infection prevalence in Ghana
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Ghanaians about the transmission pathways of the dis-
ease. For instance, Mutocheluh and Kwarteng [62], re-
ported that among 200 barbers in Kumasi none (0 %) of
the barbers could describe the common HCV transmis-
sion pathways and only 7 % were aware that sharing razor
blade or hair trimmer could be a means of transmitting
viral pathogens like HCV and HBV. Similar trends of low
awareness has been reported for pregnant women [63].
Additionally, while the transmission dynamics of HCV re-
mains varied and include unprotected sex, mother-to-
child transmission and transfusion of infected blood, in
many Ghanaian communities, there has been an over-
emphasis on HCV and related viral hepatitis as sexually
transmitted infections (STIs) [13]. Such perceptions
have often led to HCV-positive individuals been stig-
matized and at times discouraged such patients seeking
proper care to minimise their chances of spreading the
disease.
Controlling HCV will require three (3) key strategies
which include offering treatment for infected individuals,
implementing measures to halt the transmission of the
disease and reducing mortality arising from unmanaged
complications such as HCC [7]. Antiviral medications
have shown great potency in curing HCV infections (ap-
proximately 90 % of infections) but access to these medi-
cines remain poor in many developing countries including
Ghana [64]. To ensure that such therapies are available to
majority of chronic HCV sufferers in Ghana, they must be
provided freely under the country’s National Health Insur-
ance Scheme (NHIS). This must be one of the key focus
or priority for the government considering that wider
availability of highly effective new generation direct-acting
antiviral medications to treat HCV infections would not
only reduce the occurrence of complications such as HCC
but will also lead to decline in prevalence of the disease
arising from altered infectivity state of treated individuals.
Unfortunately, unlike HBV, a vaccine for HCV is cur-
rently unavailable and therefore interruption of infection
transmission through risk reduction would rely mainly
on education to improve knowledge and awareness of
the transmission dynamics of the disease. While routine
screening of the general population may not be recom-
mended as it’s deemed to be not cost effective, screening
of high-risk groups such as injection drug users (IDUs)
and persons with high-risk sexual behaviours should be
expanded nationwide and provided possibly freely to in-
crease patronage. This should be backed with other in-
novative strategies such as provision of comprehensive
harm-reduction services to injection drug users including
sterile injecting equipment [64]. Additionally, attention
needs to be paid to conditions in the prisons as the risk of
HCV infection remains high in these settings. Agyei et al.
[38], reported that as much as 35.2 % of prisoners reported
ever injecting drugs and of these 11.5 % were HIV-
positive. Public health interventions should aim at ad-
dressing the specific needs of such populations as they
may pose additional transmission risk once released
into the community [37, 38].
Horizontal transmission of HCV has been recognized
to be linked to factors such as age, socioeconomic/living
conditions as well as other risky behaviours such as
sharing towels, dental cleaning materials and chewing
gum [45]. Martinson et al. [45], for instance, has demon-
strated that general improvements in socio-economic con-
ditions may lead to a decreased exposure to viral hepatitis
including hepatitis B and HCV among Ghanaians. Over
the last few decades, there have been significant improve-
ment in the living conditions of Ghanaians. For instance,
the percentage of Ghanaians with improved access to
water increased from 56.0 % in 1990 to 86.0 % in 2012
[65]. The proportion of Ghanaians classified as poor
has also decreased by more than 50 % from 52.6 % in
1991 to 21.4 % in 2012 [66]. Although, studies con-
ducted after 2005 generally reported lower HCV preva-
lence than those conducted before, in the context of
limited data it is difficult to assess the extent to which
general improvements in socioeconomic conditions have
contributed to reductions in the HCV burden across the
country and for different regions. The high prevalence of
HCV in Greater Accra may be due to the region’s national
status of harbouring the capital city. This has often re-
sulted in a high influx of both young and old into its com-
mercial areas from all corners of the country and
internationally for business, tourism or to seek greener
pastures, an atmosphere which provides a conducive en-
vironment for the promotion of anti-social behaviours
such as drug abuse and prostitution; patterns which may
facilitate HCV transmission [67].
Although, limited studies have been conducted to evalu-
ate the impact of chronic HCV infection on Ghana’s health
system and economy in general, the impact arising from
the high prevalence of the disease may be enormous owing
to significant mortality and costs associated with complica-
tions such as HCC and liver cirrhosis. The contribution of
HCV to liver cirrhosis was demonstrated in a study by
Blankson et al. [37], which identified that chronic HCV in-
fection was implicated in 1 in 14 liver cirrhosis cases. Treat-
ment for chronic HCV is deemed to be expensive. A
standard 12-week treatment with one of the newer drugs
Sovaldi® (Sofosbuvir) cost around US $ 84,000 which breaks
down to $1000 for each pill taken daily [68]. This is cer-
tainly a cost that most HCV Ghanaians cannot afford nei-
ther could it be absorbed by any sustainable public funding.
While generic versions of such medications cost signifi-
cantly less, there remains major availability issues. The high
prevalence of HCV infection in HIV patients is also likely
to increase mortality in such groups. While majority of
studies did not document the most prevalent age groups,
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high HCV burden is likely to impact on economic growth
as productivity among affected persons are likely to be af-
fected and their general wellbeing diminished. Thus, high
HCV burden can have significant impact on Ghana’s econ-
omy and as such a strong economic argument for govern-
ment commitment and intervention in tackling the disease
should be made.
Reducing the overall burden of chronic HCV infection in
Ghana will require new measures and strategies and the
recognition of the disease as one of the key country’s prior-
ity areas. Recently, the World Health Organization (WHO)
introduced updated guidelines as a framework for countries
to plan the expansion of clinical services to persons suffer-
ing chronic HCV infection [69]. The guideline highlights
nine (9) key areas such as screening of high-risk, groups,
mitigating liver damage through measures such as alcohol
assessment and treatment with appropriate regimen such
as interferon [69]. The government of Ghana would need
to pay closer attention to implementing the recommenda-
tions set out in this guideline if the battle against HCV is to
be won. Tackling the burden of chronic HCV infection in
Ghana would also require stronger commitments from
government and all other interest groups with the objective
of ensuring that measures to control HCV are fully incor-
porated in national policies. The role of civil societies and
pressure groups in driving such changes have been widely
recognized and their involvement in for instance, the fight
against the HIV/AIDS epidemic has been referenced as a
remarkable achievement including successfully pushing for
the reduction in the cost of ARTs. The successes and ex-
perience from HIV/AIDS epidemic should guide future
strategies against viral hepatitis such as HCV [70].
Strengths and limitations
The screening method employed can significantly impact
on the HCV prevalence rate [71]. Since our review cov-
ered a two decade period, the studies adopted different
screening techniques there are likely vary in terms of
sensitivity and specificity which could partly account for
the difference in prevalence rates across studies pub-
lished in different years. As indicated by Fox [72], it can
be extremely difficult to differentiate acute from chronic
HCV infection especially in patients who have not previ-
ously undergone anti-HCV testing and it is possible that
the prevalence rate reported in some studies may not be
representative of only chronic infections. While this re-
view highlights a growing evidence in this area of research
as depicted by almost half (48 %) of studies were recently
published (within last 5 years), there are significant re-
gional variations. Nearly two-thirds (75 %) of studies as
well as around 90 % of total population size involved were
from two regions (Ashanti and Greater Accra), although
these two regions represented just a little over 35 % of the
country’s population in 2010 [73]. Also it was not possible
to deduce aggregate HCV prevalence estimates for seven
regions and no data was retrieved from the upper west re-
gion. A wider epidemiological study conducted around the
same time may help to provide a more accurate preva-
lence estimate as well as minimize the wide heterogeneity
as observed in the studies reviewed. Additionally, most
studies involved adult participants with only one study
specifically conducted in children [45]. Likewise, most
studies reported no information on HCV prevalence in re-
lation to demographic (e.g. age and sex) and socio-
economic (e.g. education) as well as risk profiles (e.g.
blood transfusion, multiple injection drug use, HIV status)
which are all known predictors of HCV status [74]. It will
be important for future research to look into the epidemi-
ology of HCV in the underrepresented regions as well as
targeted high-risk groups to provide greater insight into
the HCV burden in Ghana. In spite of the above limita-
tions, this review presents a more rigorous estimate of
chronic HCV infection in Ghana that should inform
health planning, policy decisions and the design of public
health strategies by the ministry of Health and the Ghana
Health service towards controlling the disease.
Conclusion
This study has documented a high prevalence of chronic
HCV infection in Ghana. The results highlight the need
for urgent public health interventions aimed at reducing
the infection rate. These must include efforts to increase
awareness and knowledge about HCV transmission dy-
namics, targeting the screening of high-risk groups and
providing treatment for affected individuals. Further re-
search is also needed to understand fully the population
factors underlying this high HCV prevalence. New studies
particularly in underrepresented regions and high-risk
population groups are urgently needed to offer better per-
spective on the overall HCV burden in Ghana.
Abbreviations
HCV, hepatitis C virus; WHO, World Health Organization; HBV, hepatitis B
virus; Anti-HCV, hepatitis C antibody; NHIS, National health insurance scheme;
HDI, human development index; HIV, human immunodeficiency virus;
STI, sexually transmitted infection
Funding
None.
Availability of data and materials
We declare that the data supporting the conclusions of this article are fully
described within the article.
Authors’ contributions
AA and RO designed the study and drafted an outline. AA, RO, AM and GA
participated in data analysis, draft of initial manuscript and approved the
final content off this manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Agyeman et al. BMC Infectious Diseases  (2016) 16:391 Page 12 of 14
Ethics approval and consent to participate
Not applicable.
Author details
1Research Unit, Health Policy Consult, P. O. Box WJ 537, Weija-Accra, Ghana.
2Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Received: 8 March 2016 Accepted: 12 July 2016
References
1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbial Infect.
2011;17:107–15.
2. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes
E. Global distribution and prevalence of hepatitis C virus genotypes.
Hepatology. 2015;61(1):77–87.
3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology
and genotype distribution of the hepatitis C virus infection. J Hepatol.
2014;61(1 Suppl):S45–57.
4. The Global burden of Hepatitis C working Group. Global burden of disease
(GBD) for hepatitis C. J Clin Pharmacol. 2004;44:20–9.
5. Di Bisceglie AM, Order SE, Klein JL, et al. The role of chronic viral hepatitis
in hepatocellular carcinoma in the United States. Am J Gastroenterol.
1991;86:335–8.
6. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of
hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver
cancer worldwide. J Hepatol. 2006;45(4):529–38.
7. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C:
considerations for healthcare providers in the United States. Clin Infect
Dis. 2012;55 Suppl 1:S10–5.
8. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus
infection in sub-Saharan Africa. Lancet Infect Dis. 2002;2(5):293–302.
9. Rao VB, Johari N, du Cros P, Messina J, Ford N, Cooke GS. Hepatitis C
seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic
review and meta-analysis. Lancet Infect Dis. 2015;15(7):819–24.
10. Layden JE, Phillips R, Opare-Sem O, Akere A, Luke A, Tayo BO, Cooper RS.
Hepatitis C in sub-Saharan Africa: urgent need for attention. Open Forum
Infect Dis. 2014;1(2):ofu065.
11. Alter MJ. Epidemiology of hepatitis C infection. World J Gastroenterol.
2007;13(17):2436–41.
12. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology
of hepatitis C virus infection: new estimates of age-specific antibody to HCV
seroprevalence. Hepatology. 2013;57(4):1333–42.
13. Adler M, Goubau P, Nevens F, Van Vlierberghe H. Hepatitis C virus: the
burden of the disease. Acta Gastroenterol Belg. 2002;65:83–6.
14. Razavi H, ElKhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R.
Chronic Hepatitis C Virus (HCV) disease burden and cost in the United
States. Hepatology. 2013;57(6):2164–70.
15. Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K, Ramji A,
Estes C, Razavi H, Sherman M. Burden of disease and cost of chronic hepatitis C
virus infection in Canada. Can J Gastroenterol Hepatol. 2014;28(5):243–50.
16. Hepatitis Foundation of Ghana. Viral Hepatitis in Ghana: The Role of the
Government. 2014. Available online at http://theobaldhepb.org/?page_
id=624. Accessed 01 Jan 2016.
17. Ampofo W, Nii-Trebi N, Ansah J, Abe K, Naito H, Aidoo S, Nuvor V, Brandful J,
Yamamoto N, Ofori-Adjei D, Ishikawa K. Prevalence of blood-borne infectious
diseases in blood donors in Ghana. J Clin Microbiol. 2002;40(9):3523–5.
18. Riou J, Aït Ahmed M, Blake A, Vozlinsky S, Brichler S, Eholié S, Boëlle PY,
Fontanet A. HCV epidemiology in Africa group. Hepatitis C virus
seroprevalence in adults in Africa: a systematic review and meta-analysis. J
Viral Hepat. 2016;23(4):244–55.
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Ann Intern
Med. 2009;151(4):264–9. w64.
20. Gretch DR. Diagnostic tests for hepatitis C. Hepatology. 1997;26(3 Suppl 1):43S–7.
21. Musa B, Bussell S, Borodo MM, Samaila AA, Femi OL. Prevalence of hepatitis B
virus infection in Nigeria, 2000–2013: A systematic review and meta-analysis.
Niger J Clin Pract. 2015;18:163–72.
22. Downs SH, Black N. The feasibility of creating a checklist for the assessment
of the methodological quality both of randomized and non-randomized
studies of health care interventions. J Epidemiol Community Health.
1998;52(6):377–84.
23. Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing
the gap between methodologists and end-users: R as a computational
back-end. J Stat Softw. 2012;49:5.
24. StatsDirect. Proportion Meta-analysis http://www.statsdirect.com/help/
default.htm#meta_analysis/proportion.htm. Accessed 04 Feb 2016.
25. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency
in meta-analyses. Br Med J. 2003;327(7414):557–60.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ. 1997;315:629–34.
27. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in
meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;
25(20):3443–57.
28. Higgins JP. Commentary: Heterogeneity in meta-analysis should be
expected and appropriately quantified. Int J Epidemiol. 2008;37(5):1158–60.
29. Acquaye JK, Tettey-Donkor D. Frequency of hepatitis C virus antibodies and
elevated serum alanine transaminase levels in Ghanaian blood donors. West
Afr J Med. 2000;19(4):239–41.
30. Adoba P, Boadu SK, Agbodzakey H, Somuah D, Ephraim RK, Odame EA.
High prevalence of hepatitis B and poor knowledge on hepatitis B and C
viral infections among barbers: a cross-sectional study of the Obuasi
municipality, Ghana. BMC Public Health. 2015;15:1041.
31. Adjei AA, Armah HB, Gbagbo F, Ampofo WK, Quaye IK, Hesse IF, Mensah G.
Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C
virus and syphilis among prison inmates and officers at Nsawam and Accra,
Ghana. J Med Microbiol. 2006;55(Pt 5):593–7.
32. Adjei AA, Armah HB, Gbagbo F, Ampofo WK, Boamah I, Adu-Gyamfi C,
Asare I, Hesse IF, Mensah G. Correlates of HIV, HBV, HCV and syphilis
infections among prison inmates and officers in Ghana: A national
multicenter study. BMC Infect Dis. 2008;8:33.
33. Allain JP, Opare-Sem O, Sarkodie F, Rahman R, Owusu-Ofori S. Deferred donor
care in a regional hospital blood center in Ghana. Transfusion. 2009;49(4):669–75.
34. Allain JP, Sarkodie F, Asenso-Mensah K, Owusu-Ofori S. Relative safety of first-time
volunteer and replacement donors in West Africa. Transfusion. 2010;50(2):340–3.
35. Amidu N, Owiredu WB, Addai-Mensah O, Alhassan A, Quaye L, Batong B.
Seroprevalence and risk factors for human immunodeficiency virus, hepatitis
B and C viruses infections among blood donors at the Bolgatanga Regional
Hospital in Bolgatanga, Ghana. J Ghana Sci Assoc. 2010;12:1.
36. Apea-Kubi KA, Yamaguchi S, Sakyi B, Ofori-Adjei D. HTLV-1 and other viral
sexually transmitted infections in antenatal and gynaecological patients in
Ghana. West Afr J Med. 2006;25(1):17–21.
37. Blankson A, Wiredu EK, Adjei A, Tettey Y. Seroprevalence of hepatitis B and C
viruses in cirrhosis of the liver in Accra, Ghana. Ghana Med J. 2005;39(4):132–7.
38. Candotti D, Sarkodie F, Allain JP. Residual risk of transfusion in Ghana. Br J
Haematol. 2001;113(1):37–9.
39. Candotti D, Temple J, Sarkodie F, Allain JP. Frequent recovery and broad
genotype 2 diversity characterize hepatitis C virus infection in Ghana, West
Africa. J Virol. 2003;77(14):7914–23.
40. Ephraim R, Nsiah P, Osakunor D, Adoba P, Sakyi S, Anto E. Seroprevalence of
hepatitis B and C viral infections among type 2 diabetics: a cross-sectional
study in the cape coast metropolis. Ann Med Health Sci Res. 2014;4(5):719–22.
41. Ephraim R, Donkor I, Sakyi SA, Ampong J, Agbodjakey H. Seroprevalence
and risk factors of hepatitis B and hepatitis C infections among pregnant
women in the Asante Akim North Municipality of the Ashanti region,
Ghana; a cross sectional study. Africa Health Sci. 2015;15(3):709–13.
42. King S, Adjei-Asante K, Appiah L, Adinku D, Beloukas A, Atkins M, Sarfo SF,
Chadwick D, Phillips RO, Geretti AM. Antibody screening tests variably
overestimate the prevalence of hepatitis C virus infection among HIV-
infected adults in Ghana. J Viral Hepat. 2015;22(5):461–8.
43. Kubio C, Tierney G, Quaye T, Nabilisi JW, Ziemah C, Zagbeeb SM, Shaw S,
Murphy WG. Blood transfusion practice in a rural hospital in Northern
Ghana, Damongo, West Gonja District. Transfusion. 2012;52(10):2161–6.
44. Lassey AT, Damale NK, Bekoe V, Klufio CA. Hepatitis C virus seroprevalence
among mothers delivering at the Korle-Bu Teaching Hospital, Ghana. East
Afr Med J. 2004;81(4):198–201.
45. Martinson FE, Weigle KA, Mushahwar IK, Weber DJ, Royce R, Lemon SM.
Seroepidemiological survey of hepatitis B and C virus infections in Ghanaian
children. J Med Virol. 1996;48(3):278–83.
46. Nkrumah B, Owusu M, Frempong HO, Averu P. Hepatitis B and C viral infections
among blood donors from rural Ghana. Ghana Med J. 2011;45(3):97–100.
Agyeman et al. BMC Infectious Diseases  (2016) 16:391 Page 13 of 14
47. Owusu-Ofori S, Temple J, Sarkodie F, Anokwa M, Candotti D, Allain JP.
Predonation screening of blood donors with rapid tests: implementation
and efficacy of a novel approach to blood safety in resource-poor settings.
Transfusion. 2005;45(2):133–40.
48. Sagoe KW, Agyei AA, Ziga F, Lartey M, Adiku TK, Seshi M, Arens MQ, Mingle
JA. Prevalence and impact of hepatitis B and C virus co-infections in
antiretroviral treatment naïve patients with HIV infection at a major
treatment center in Ghana. J Med Virol. 2012;84(1):6–10.
49. Sarkodie F, Adarkwa M, Adu-Sarkodie Y, Candotti D, Acheampong JW.
Screening for viral markers in volunteer and replacement blood donors in
West Africa. Vox Sang. 2001;80:142–7.
50. Walana W, Ahiaba S, Hokey P, Vicar EK, Acuqah SEK, Der EM, Ziem TB. Sero-
prevalence of HIV, HBV and HCV among blood donors in the Kintampo
Municipal Hospital, Ghana. British Microbiol Res J. 2014;4(12):1491–9.
51. Wansbrough-Jones MH, Frimpong E, Cant B, Harris K, Evans MR, Teo CG.
Prevalence and genotype of hepatitis C virus infection in pregnant women
and blood donors in Ghana. Trans R Soc Trop Med Hyg. 1998;92(5):496–9.
52. Holtzman D. Hepatitis C. http://wwwnc.cdc.gov/travel/yellowbook/2016/
infectious-diseases-related-to-travel/hepatitis-c. Accessed 02 Mar 2016.
53. Daw MA. Transmission of Hepatitis C. http://www.esciencecentral.org/
ebooks/hepatitis/transmission-of-hepatitis-c-virus.php. Accessed 05 June
2016.
54. Sandesh K, Varghese T, Harikumar R, Beena P, Sasidharan VP, Bindu CS, Tony
J, Harish K, Sunilkumar K, Ramachandran TM. Prevalence of hepatitis B and
C in the normal population and high risk groups in north Kerala. Trop
Gastroenterol. 2006;27(2):80–3.
55. Wang CS, Chang TT, Yao WJ, Chou P. Comparison of hepatitis B virus and
hepatitis C virus prevalence and risk factors in a community-based study.
Am J Trop Med Hyg. 2002;66(4):389–93.
56. Edgren G, Tran TN, Hjalgrim H, Rostgaard K, Shanwell A, Titlestad K, Wikman
A, Norda R, Jersild C, Wideroff L, Gridley G, Adami J, Melbye M, Nyrén O,
Reilly M. Improving health profile of blood donors as a consequence of
transfusion safety efforts. Transfusion. 2007;47(11):2017–24.
57. Ofori-Asenso R, Agyeman A. Hepatitis B in Ghana: a systematic review and
meta-analysis of prevalence studies (1995–2015). BMC Infect Dis. 2016;16(1):130.
58. World Health Organization. Ghana National blood Policy. http://www.who.
int/bloodsafety/transfusion_services/GhanaNationalBloodPolicy2006.pdf.
Accessed 10 Jan 2016.
59. Yeung CY, Lee HC, Chan WT, et al. Vertical transmission of hepatitis C virus:
current knowledge and perspectives. World J Hepatol. 2014;6(9):643–51.
60. Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. Pregnancy
outcomes associated with viral hepatitis. J Viral Hepat. 2011;18:e394–8.
61. Pergam SA, Wang CC, Gardella CM, Sandison TG, Phipps WT, Hawes SE.
Pregnancy complications associated with hepatitis C: data from a 2003–2005
Washington state birth cohort. Am J Obstet Gynecol. 2008;199:38. e1–38.e9.
62. Mutocheluh M, Kwarteng K. Knowledge and occupational hazards of
barbers in the transmission of hepatitis B and C was low in Kumasi, Ghana.
Pan Afr Med J. 2015;20:260.
63. Cheng A, Jose J, Larsen-Reindorf R, Small C, Nde H, Dugas L, Ehrhardt S,
Nelson K, Ezeanolue E, Layden J. A survey study of pregnant women and
healthcare practitioners assessing the knowledge of attitudes and practices
of hepatitis B management at a teaching Hospital in Kumasi, Ghana, West
Africa. Open Forum Infect Dis. 2015;2(4):ofv122.
64. World Health Organization. Hepatitis C. http://www.who.int/mediacentre/
factsheets/fs164/en/. Accessed 08 Mar 2016.
65. Trading economics. Improved water source (% of population with access) in
Ghana http://www.tradingeconomics.com/ghana/improved-water-source-
percent-of-population-with-access-wb-data.html. Accessed 08 Mar 2016.
66. World Bank. Poverty reduction in Ghana: Progress and Challenges http://
www.worldbank.org/en/country/ghana/publication/poverty-reduction-
ghana-progress-challenges. Accessed 02 Mar 2016.
67. Dennis-Antwi J, Adjei S, Asare JB, Twene R. A national Survey on prevalence
and social consequences of substance (drug) use among second cycle and
out of school youth in Ghana. http://www.who.int/countries/gha/
publications/substance_abuse_report.pdf. Accessed June 5 2016.
68. Gokhale K, Kitamura M. $10 Copy of Gilead Blockbuster Sovaldi Appears in
Bangladesh. http://www.bloomberg.com/news/articles/2015-03-08/-10-copy-
of-gilead-s-blockbuster-sovaldi-appears-in-bangladesh. Accessed 02 Mar 2016.
69. World Health Organization. Guidelines for the screening, care and treatment
of persons with hepatitis C infection http://www.who.int/hiv/pub/hepatitis/
hepatitis-c-guidelines/en/. Accessed Mar 15 2016.
70. Lemoine M, Eholié S, Lacombe K. Reducing the neglected burden of viral
hepatitis in Africa: strategies for a global approach. J Hepatol. 2015;62(2):469–76.
71. Alter MJ, Kuhnert WL, Finelli FL. Guidelines for laboratory testing and result
reporting of antibody to hepatitis C virus*. http://www.cdc.gov/mmwr/
preview/mmwrhtml/rr5203a1.htm. Accessed 08 Mar 2016.
72. Fox RK. Core concepts. Diagnosis of acute HCV infection. http://www.
hepatitisc.uw.edu/go/screening-diagnosis/acute-diagnosis/core-concept/all.
Accessed 08 Mar 2016
73. Ghana Statistical Service. 2010 Population and Housing Census; Summary
report of final results.http://www.statsghana.gov.gh/docfiles/2010phc/
Census2010_Summary_report_of_final_results.pdf. Accessed 01 Mar 2016.
74. Gelberg L, Robertson MJ, Arangua L, Leake BD, Sumner G, Moe A, Andersen
RM, Morgenstern H, Nyamathi A. Prevalence, distribution, and correlates of
hepatitis C virus infection among homeless adults in Los Angeles. Public
Health Rep. 2012;127(4):407–21.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Agyeman et al. BMC Infectious Diseases  (2016) 16:391 Page 14 of 14
